[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biomarin Pharmaceuticals (BMRN)

Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

BioMarin's Enzyme Portfolio Momentum Collides With Margin Questions the Street Hasn't Asked Yet

BioMarin Pharmaceutical (BMRN) reports first-quarter 2026 earnings on May 4, with investors focused on whether the rare disease specialist can sustain momentum after a volatile 2025 that saw dramatic swings between beats and misses. The central question: can BMRN deliver consistent execution on its commercial portfolio and pipeline progress, or will operational challenges continue to create earnings unpredictability?

BioMarin Pharmaceutical develops and commercializes therapies for rare genetic diseases, with a portfolio spanning enzyme replacement therapies, gene therapies, and small molecule treatments across metabolic, hematologic, and skeletal disorders. The company's revenue is driven by established products like Vimizim, Naglazyme, and Kuvan, alongside newer launches...

Fundamentals

See More
  • Market Capitalization, $K 10,448,177
  • Shares Outstanding, K 193,270
  • Annual Sales, $ 3,221 M
  • Annual Income, $ 348,900 K
  • EBIT $ 429 M
  • EBITDA $ 504 M
  • 60-Month Beta 0.23
  • Price/Sales 3.23
  • Price/Cash Flow 18.89
  • Price/Book 1.70

Options Overview Details

View History
  • Implied Volatility 45.09% (+2.19%)
  • Historical Volatility 25.16%
  • IV Percentile 84%
  • IV Rank 62.91%
  • IV High 55.46% on 02/23/26
  • IV Low 27.50% on 01/15/26
  • Expected Move (DTE 11) 4.21 (7.78%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 887
  • Volume Avg (30-Day) 1,221
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 33,248
  • Open Int (30-Day) 35,331
  • Expected Range 49.85 to 58.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.78
  • Number of Estimates 8
  • High Estimate $0.99
  • Low Estimate $0.54
  • Prior Year $0.98
  • Growth Rate Est. (year over year) -20.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
52.46 +3.06%
on 04/29/26
57.76 -6.41%
on 04/08/26
-3.18 (-5.56%)
since 04/01/26
3-Month
52.46 +3.06%
on 04/29/26
66.28 -18.43%
on 02/24/26
-2.48 (-4.39%)
since 01/30/26
52-Week
50.76 +6.50%
on 11/07/25
66.28 -18.43%
on 02/24/26
-8.65 (-13.79%)
since 05/01/25

Most Recent Stories

More News
BioMarin's Enzyme Portfolio Momentum Collides With Margin Questions the Street Hasn't Asked Yet

Barchart Research What to Expect from BMRN Earnings BMRN Generated May 1, 2026 Current Price $54.06 EPS Estimate $$0.81 Consensus Rating Moderate Buy Average Move 4.13% BioMarin's Enzyme Portfolio Momentum...

BMRN : 54.06 (+0.28%)
BioMarin Pharmaceutical (BMRN) Reports Earnings Tomorrow: What To Expect

BioMarin Pharmaceutical (BMRN) Reports Earnings Tomorrow: What To Expect

BMRN : 54.06 (+0.28%)
BioMarin's Enzyme Portfolio Momentum Collides With Margin Questions the Street Hasn't Asked Yet

Barchart Research What to Expect from BMRN Earnings BMRN Generated May 1, 2026 Current Price $54.06 EPS Estimate $$0.81 Consensus Rating Moderate Buy Average Move 4.13% BioMarin's Enzyme Portfolio Momentum...

BMRN : 54.06 (+0.28%)
BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting

VOXZOGO is the only approved treatment for children with achondroplasia starting at birth, with over 10 years of clinical research demonstrating the long-term benefit on complications associated with achondroplasia...

BMRN : 54.06 (+0.28%)
BioMarin's Enzyme Portfolio Momentum Collides With Margin Questions the Street Hasn't Asked Yet

Barchart Research What to Expect from BMRN Earnings BMRN Generated May 1, 2026 Current Price $54.06 EPS Estimate $$0.81 Consensus Rating Moderate Buy Average Move 4.13% BioMarin's Enzyme Portfolio Momentum...

BMRN : 54.06 (+0.28%)
BioMarin Completes Acquisition of Amicus Therapeutics

Acquisition Adds Galafold ® (migalastat) for Fabry Disease and Pombiliti ® (cipaglucosidase alfa-atga) + Opfolda ® (miglustat) for Pompe Disease to BioMarin's...

BMRN : 54.06 (+0.28%)
BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET

SAN RAFAEL, Calif. , April 27, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host...

BMRN : 54.06 (+0.28%)
BioMarin Announces Board Leadership Transition

Ian T. Clark elected Chair of the Board; Richard A. Meier to retire

BMRN : 54.06 (+0.28%)
2 Profitable Stocks with Promising Prospects and 1 Facing Challenges

2 Profitable Stocks with Promising Prospects and 1 Facing Challenges

GMED : 91.34 (+1.29%)
BMRN : 54.06 (+0.28%)
BL : 33.91 (+8.51%)
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

HIMS : 27.41 (+0.88%)
BMRN : 54.06 (+0.28%)
REGN : 701.42 (-0.80%)
MRNA : 45.37 (-1.24%)
BIIB : 187.06 (-1.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder),...

See More

Key Turning Points

3rd Resistance Point 55.11
2nd Resistance Point 54.70
1st Resistance Point 54.38
Last Price 54.06
1st Support Level 53.65
2nd Support Level 53.24
3rd Support Level 52.92

See More

52-Week High 66.28
Fibonacci 61.8% 60.35
Fibonacci 50% 58.52
Fibonacci 38.2% 56.69
Last Price 54.06
52-Week Low 50.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.